1. Introduction {#sec1}
===============

Research on tumor-associated antigen (TAA) peptides has identified a large collection of peptide epitopes that have been and are being used for the vaccination of cancer patients \[[@bib1]\]. The use of peptide-based vaccines offers several potential advantages, such as the simplicity of peptide administration in the clinical setting, the possibility of treating only those patients whose tumors overexpress the antigens, and the availability of *in vitro* or *ex vivo* assays that can assess patients' immune response to vaccine epitopes.

Over the last twenty years, the implementation of novel methodologies such as next generation sequencing and bioinformatics tools led to the identification of several TAAs. Among all recognized TAAs, a great interest has been focused on cancer testis (CT) and differentiation antigens, which are frequently downregulated in somatic adult tissues, while become aberrantly re-expressed in various malignancies \[[@bib2], [@bib3], [@bib4]\]. These features render these antigens as appealing targets to generate anti-cancer vaccines and other types of immunotherapy. Moreover, several works suggest the association between TAAs expression and poorer outcomes across a broad spectrum of solid tumors, as well as a higher prevalence in undifferentiated and advanced-stage cancers \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9]\]. As a result, intense research efforts have been directed toward the possible use of TAAs in the development of therapeutic vaccines due to their potent immunogenicity \[[@bib10]\]. Several clinical trials with vaccines containing TAAs, such as New York esophageal squamous cell carcinoma-1 (NY-ESO-1), Wilms tumor antigen (WT-1) and PReferentially expressed Antigen of MElanoma (PRAME), accrued or are actually accruing patients with melanoma, lung, ovarian, and breast cancers \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\]. However, only few studies have investigated the expression of these TAAs in breast cancer and, in particular, across breast cancer subtypes \[[@bib20], [@bib21], [@bib22], [@bib23], [@bib24]\].

The aim of this study was to assess the immunoreactivity for the TAAs NY-ESO-1, PRAME and WT-1 in a large series of breast cancer tumor samples classified, according to immunophenotype, in triple negative (TN), Luminal B-like, lobular type, human epidermal growth factor receptor 2 (HER2)-positive, and estrogen receptor (ER)- and progesterone receptor (PgR)-positive (Luminal A-like) human breast cancers.

2. Material and methods {#sec2}
=======================

2.1. Study population {#sec2.1}
---------------------

Demographic, clinical, and pathological data of consecutive early breast cancer patients who underwent surgery at the European Institute of Oncology (Milan, Italy) between June 1995 and July 2002 were collected from the institutional database. Tumor types were classified according to the World Health Organization Histological Classification of Breast Tumors, as modified by Rosen and Obermann \[[@bib25]\]. Tumor grading was assessed according to Elston and Ellis criteria \[[@bib23]\].

A total of 250 cases of invasive breast cancer were selected and categorized, according to ER, PgR, HER2 status, and Ki67 labelling index, in: Luminal B like, defined as ER-positive with Ki67 \> 14% (n = 50); Luminal A like, defined as ER- and/or PgR-positive more than 50% (N = 50); lobular histology (n = 50); HER2-positive, defined as any ER/PgR status and HER2+ (n = 50); and TN, defined as the lack of ER, PgR, and HER2 (n = 50).

All cases were examined for NY-ESO-1, PRAME and WT1 expression by immunohistochemistry (IHC).

2.2. Immunohistochemistry {#sec2.2}
-------------------------

ER, PgR status, Ki-67 labelling index (determined with the MIB1 monoclonal antibody) were assessed as previously reported \[[@bib24],[@bib25]\]. HER2 IHC expression was evaluated using a 1/400 dilution of a polyclonal antiserum (Dako, Glostrup, Denmark). All tumors with equivocal (IHC 2+) results were tested for gene amplification by fluorescence *in situ* hybridization (FISH; Vysis PathVysion; Abbott, Chicago, IL), according to the international guidelines \[[@bib26]\].

We defined as ER-positive tumors those showing ER and PgR expression in ≥50% neoplastic cells. Triple negative tumors were characterized by lack of immunoreactivity for ER and PgR, and by a negative (by both IHC and FISH) HER2 status. Slides were hybridized with probes to LSI HER-2/neu and CEP17.

NY-ESO-1 (monoclonal antibody E978 provided by Ludwig Institute for Cancer Research, at a working dilution of 1:200, and polyclonal antibody 195 provided by GSK, at a working dilution of 1:4000), WT1 (DakoCytomation, monoclonal antibody 6F--H2, at a working dilution of 1:200) and PRAME (Abcam, policlonal antibody ab32185, at a working dilution of 1:1600) expression has been investigated by IHC on whole tissue sections. Tissue specimens were dewaxed and heated in an antigen retrieval solution \[EDTA buffer (1 mM, pH 8.0)\] at 99 °C for 15 min (NY-ESO-1 monoclonal antibody) or 30 min (NY-ESO-1 polyclonal antibody, WT1 and PRAME). The sections were then incubated with the antibodies overnight at 4 °C (NY-ESO-1 monoclonal antibody and PRAME) or for 30 min at room temperature (NY-ESO-1 polyclonal antibody and WT1). The DAKO EnVision Mouse was used as a detection system and diaminobenzidine tetrahydrochloride as a chromogen. Sections of normal human testis were used as positive control for NY-ESO-1 and PRAME reactions; vascular endothelium was used as positive inner control for WT1.

2.3. Scoring {#sec2.3}
------------

NY-ESO-1, PRAME, and WT-1 immunohistochemical results were scored using a semiquantitative scoring system similar to the previously described immunohistochemical-score \[[@bib27]\]. This method considers both the percentage of immune-reactive cells and the staining intensity. The percentage of positive cells is then multiplied by the intensity of staining (1+, 2+, or 3+), and the final score ranges from 0 (no staining) to 300 (diffuse and strong immunostaining of all the tumor cells).

2.4. Statistical methods {#sec2.4}
------------------------

Antigen expression (presence versus absence) among groups was evaluated using Fisher's exact test (two proportions) or a chi-square test (more than two proportions). Different cut-offs of expression (i.e. 1+, 2 + and 3+) were considered to define presence of antigen expression. Kruskal-Wallis test was used for comparison of expression scores among different groups. P-values less than 0.05 were considered as statistically significant. All tests were two-sided.

3. Results {#sec3}
==========

3.1. Pathological characteristics {#sec3.1}
---------------------------------

From June 1995 to July 2002, a total of 4000 pT1-3 pN0-3 M0 early breast cancer patients were included in the institutional database. Among this patient population, a total of 250 cases of invasive breast cancer were identified. Tumor stage was pT1a-c for 174 patients, pT2 for 67 patients 3 and pT3-4 for 9 patients. Nodal involvement was present in 84 patients, while 166 were staged as pN0/pNX.

According to the histotype, 200 tumors were classified as invasive ductal and 132 displayed a Ki67 labelling index ≥20%. Lobular histology was identified in 50 cases. Baseline pathological characteristics of all breast tumors are listed in [Table 1](#tbl1){ref-type="table"}.Table 1Baseline pathological characteristics, according to group.Table 1Luminal A-likeHER-2 positiveLobularLuminal B-likeTriple NegativeN%N%N%N%N%All samples5010050100501005010050100Histotype Ductal499842840039783570 Lobular0000501000000 Others128160011221530Grade 181651010201212 22448183640801632612 3173426520030604284 Unknown1212003612pT 140803264397831623264 210201428112215301734 3-40048004812pN 025503162336625503468 116328165101428816 2-381681636714714 x12369184812ER 000183612102050100 1-490071436102000 ≥505010025504692306000PgR 00021421632306050100 1-490019381224142800 ≥50501001020224461200Ki-67 \<20%285612244284918510 ≥20%2244387681641824590

3.2. Expression of NY-ESO-1, WT1 and PRAME in breast cancer samples {#sec3.2}
-------------------------------------------------------------------

All samples were examined for NY-ESO-1 (mono and polyclonal antibody), WT1 and PRAME expression by IHC ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}). A heterogeneous staining pattern was present within specific tumor samples, ranging from 1 + to 3+. In [Fig. 5](#fig5){ref-type="fig"}**,** the visual scale shows intensity (red for 3+, green for 2 + and blue for 1+) and percentage of staining for each one of the tumor samples. The expression of all antigens in the different subpopulations of breast cancer are summarized in [Table 2](#tbl2){ref-type="table"}.Fig. 1**Example of assessing H-score in a case of breast cancer tested for NY-ESO-1.** In this picture, about half of the neoplastic cells is stained with the brown chromogen and the remaining half of the cells is blue (no staining). Cells with strongly stained nuclei (3 + positivity) are circumscribed by the red line and these cells represent about 95% of all the colored cells in the picture (95% of 50% = 47,5%); the remaining 2,5% of colored cells are cells with moderately stained nuclei (2 + positivity), marked with the red arrows, and cells with weakly stained nuclei (1 + positivity), marked with black arrows. The percentage of 2 + cells is about 2% and the percentage of 1 + cells are 0,5%. The H-score is 147, generated adding the percentage of cells for the respective intensity of staining, as follows: (50 × 0) + (0,5 × 1) + (2 × 2) + (47,5 × 3) = 147. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1Fig. 2**Comparison between mouse monoclonal NY-ESO-1 and rabbit policlonal NY-ESO-1 immunohistochemical expression in a case of triple negative infiltrating ductal carcinoma.** a,b) Mouse monoclonal NY-ESO-1 positive staining \[x 10 (a) e x 40 (b)\]. c,d) Rabbit policlonal NY-ESO-1 positive staining \[x 10 (c) e x 40 (d)\].Fig. 2Fig. 3**WT1 immunohistochemical expression.** a,b) Nuclear staining in two cases of endocrine-responsive infiltrating ductal carcinoma (x 20, *anti*-WT1). c,d) Citoplasmic staining in a case of triple-negative infiltrating ductal carcinoma (c) and in a medullary carcinoma of moderately endocrine-responsive group (d) (x 20, *anti*-WT1).Fig. 3Fig. 4**PRAME immunohistochemical expression**. a) PRAME positive staining in a lobular carcinoma (x 40, *anti*-PRAME). b) PRAME positive staining in a carcinoma of moderately endocrine-responsive group (x 40, *anti*-PRAME). c,d) PRAME positive staining in two cases of breast carcinoma with HER2 overexpression (x 40, *anti*-PRAME).Fig. 4Fig. 5Observed individual NY-ESO-1 MONO, NY-ESO-1 POLI, WT1 and PRAME antigen expression and percent staining, according to group.Fig. 5Table 2MONO NY-ESO-1, POLI NY-ESO-1, WT1 and PRAME antigen expression, according to group.Table 2AntigenExpressionLuminal A-likeHer2-positiveLobularLuminal B-likeTriple NegativepN%N%N%N%N%NY-ESO-1≥1+112236004811220.007MONO≥2+242400249180.0023+00120012816\<0.0001Score[a](#tbl2fna){ref-type="table-fn"}5 (1, 35)3 (1, 10)--2 (1207)114 (1285)0.04NY-ESO-1≥1+12361281610200.0023POLI≥2+003600369180.00073+003600248160.0015Score[a](#tbl2fna){ref-type="table-fn"}1 (1, 1)9 (3, 17)1 (1, 1)2 (1, 207)44 (1, 217)0.11WT1≥1+10206123612242856\<0.0001≥2+61236008162754\<0.00013+2400006122040\<0.0001Score[a](#tbl2fna){ref-type="table-fn"}11 (2, 99)3 (1, 30)5 (2, 5)12 (1, 265)21 (1230)0.049PRAME≥1+1217341224163212\<0.0001≥2+00816816510000.00213+00120000000.41Score[a](#tbl2fna){ref-type="table-fn"}1 (1, 1)2 (1, 65)10 (3, 70)13 (1, 80)1 (1, 1)0.15[^1]

NY-ESO-1 over-expression (score ≥2+) by monoclonal antibodies was documented in 9 (18%) TN tumors, but only in 2 (4%) ER-positive (p = 0.002). Similar results were obtained by means polyclonal antibodies against NY-ESO-1 with a higher expression in TN than in ER-positive tumors (18% vs 0%; p = 0.0007).

WT1 expression (score ≥2+) was detected in 27 (54%) TN cancers, while only in 6 (12%) and 3 (6%) cases of ER-positive and HER2-positive, respectively (p \< 0.0001). Conversely, PRAME was overexpressed (score ≥2+) in 8 (16%) HER2-positive tumor samples, while it was not expressed in TN and ER-positive tumors (p = 0.0021).

Overall, no associations were found between pathological features of disease and NY-ESO-1, WT1, and PRAME over-expression (score ≥2+) (data not showed).

4. Discussion {#sec4}
=============

Our study results showed that TN breast cancers frequently display a higher expression of WT1 and NY-ESO-1 antigens, corroborating the results of other studies that demonstrated a reduced expression of these antigens in ER-positive breast cancers as compared to TN tumors \[[@bib18], [@bib19], [@bib20], [@bib21], [@bib22],[@bib28],[@bib29]\]. Conversely, in our work we did not find significant differences in terms of PRAME expression in TN tumors as compared to other breast cancer subtypes, as suggested in previous studies \[[@bib30]\]. Such discrepancy can be partially explained by the use of monoclonal antibodies that bind different epitopes of PRAME and WT1 antigens.

DNA microarray profiling have led to the identification of invasive breast cancer subgroups with common molecular features and to the recognition of breast cancer as a heterogeneous entity \[[@bib31], [@bib32], [@bib33], [@bib34], [@bib35]\]. Choice of systemic therapies for breast cancer patients includes the identification of potential targets based on genetic signature and/or IHC \[[@bib36]\]. In this respect, the TN subtype is characterized by a higher expression of the proliferation cluster of genes \[[@bib31]\] with an elevated number of potential targets for novel therapies, included epidermal growth factor receptor (EGFR) overexpression and upregulation in endothelial growth factors \[[@bib37]\]. However, disappointing results have been obtained by targeting these molecules/pathways in the context of clinical trials \[[@bib38]\]. Interestingly, some authors revealed that human cells lacking BRCA1, including TN breast cancer cells, may be sensitive to drugs that cause double-strand breaks in DNA \[[@bib39]\] (e.g. alkylating agents) and, more recently, biological agents such as poly (ADP-ribose) polymerase inhibitors (PARP-inhibitors) \[[@bib39], [@bib40], [@bib41]\]. These preclinical and clinical evidences paved the way for implementing personalized therapies also in the TN subtype.

The identification of clinical characteristics and biomarkers associated with resistance to standard therapies represents a crucial step in the development of the most effective therapeutic approaches. Properly selecting patients who most likely benefit from a given therapy might allow to better understand patient populations and clinical setting in which investigate new therapeutic strategies. Considering breast cancer, the neoadjuvant studies represent excellent platforms to perform biomarker analysis studies and to test new drugs in selected patient populations. Indeed, TN tumors display higher rates of pathological complete response (pCR) after neoadjuvant chemotherapy compared to the hormone receptor-positive subset \[[@bib42]\]. However, several studies demonstrated that the 5-year disease-free survival (DFS) of TN tumors is significantly worse than all other breast cancer subtypes \[[@bib42],[@bib43]\]. Importantly, patients with ER-positive residual tumors present with better survival compared to patients with ER-negative tumors not achieving a pCR \[[@bib43]\]. These scant survival outcomes are also due to the limited therapeutic options currently available for TN breast cancer patients who do not achieve pCR after neoadjuvant chemotherapy. In this setting, only capecitabine monotherapy demonstrated activity, according to the CREATE-X trial results \[[@bib44]\], and it is currently the only recommended therapy for these patients in the clinical practice. In this context, the implementation of new treatments in the post-neoadjuvant setting is a topic of a great interest. Our results are of clinical relevance for such subpopulation of patients, specifically in the adjuvant and post-neoadjuvant settings of treatment. In our hypothesis, patients with TN breast cancer and residual disease after preoperative chemotherapy represent the ideal setting to test the efficacy of a vaccination strategy. To date, vaccines for breast cancer have been mainly investigated in end-stage diseases.

By contrast, ever-growing evidences suggest that immunotherapy might be most effective when administered in patients with early phase tumors and minimal burden of disease, also considering the smaller number of immune escape mechanisms adopted by tumor cells in these settings. To date, several clinical trials testing vaccines against antigens, including MUC1, CEA, and HER2, have been completed \[[@bib45]\]. In addition, other vaccines including members of the MAGE and ESO families have been tested in clinical trials for patients with melanoma and lung cancer with controversial results \[[@bib46],[@bib47]\]. Despite CT antigens potentially offer the opportunity for fostering vaccine development and therapy for a broad spectrum of cancers, other determinants involved in anti-tumor immune response have to be considered when we approach to design new trials investigating therapeutic cancer vaccines. These factors included the presence of an immune-suppressive tumor microenvironment such as the upregulation of negative immune checkpoint molecules on the tumor cells and tumor-associated immune cells as well as the presence of negative regulatory cells (T regulatory cells, myeloid-derived suppressor cells, tumor-associated macrophages etc ...). As showed in an ovarian carcinoma preclinical model, NY-ESO-1-specific/CD8+ tumor-infiltrating lymphocytes frequently upregulate the negative immune checkpoint molecules programmed of death-1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) as immune-escape mechanism \[[@bib48]\]. In addition, given the recent approval of checkpoint inhibitors-based immunotherapy in the metastatic setting of TN breast cancer \[[@bib49]\], we can speculate that some patients might benefit from the combination of a CT-based peptide vaccine and an immune checkpoint inhibitor. This hypothesis is currently being tested in some clinical trials.

5. Conclusions {#sec5}
==============

Our results demonstrated the overexpression of WT1 and NY-ESO-1 antigen in a group of patients with TN breast cancer for whom therapeutic options are limited. Exploring the expression of WT1 and NY-ESO-1 antigens in breast cancer tissue at surgery may allow to identify patients potentially candidate to adjuvant peptide vaccines, alone or in combination with other systemic therapies.
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[^1]: Median (minimum, maximum): computed only on patient with expression ≥1+.
